Table 2.
Comparisons of the characteristics of PD patients before and after initiating sacubitril-valsartan with observation period of 3–12 months.
| Variables | Before sacubitril-valsartan | After sacubitril-valsartan | P-value |
|---|---|---|---|
| CLINICAL PARAMETERS | |||
| SBP, mmHg | 144.0 (138.0–157.0) | 151.0 (124.2–162.0) | 0.925 |
| DBP, mmHg | 87.0 (75.5–101.5) | 88.5 (76.5–102.8) | 0.975 |
| Heart rate, b.p.m | 80.0 (74.5–90.5) | 75.0 (70.3–87.0) | 0.031 |
| Signs and symptoms | 21/21 | 15/21 | 0.021 |
| 24 h urine volume, ml | 700.0 (225.0–1050.0) | 700.0 (362.5–875.0) | 0.061 |
| LABORATORY VALUES | |||
| Creatinine, μmoL/L | 945.0 (790.0–1091.0) | 945.0 (674.0–1218.0) | 0.326 |
| eGFR, ml/min/1.73 m2 | 4.6 (3.9–6.5) | 4.4 (3.7–6.8) | 0.552 |
| UACR, mg/g | 2190.5 (1514.1–3933.0) | 1670.4 (1217.2–5019.5) | 0.345 |
| iPTH, pg/ml | 438.0 (211.0–597.0) | 443.0 (215.0–914.0) | 0.834 |
| Calcium, mmoL/L | 2.0 (1.9–2.2) | 2.1 (1.9–2.3) | 0.244 |
| Hemoglobin, g/L | 81.0 (74.0–92.5) | 92.0 (79.2–102.5) | 0.079 |
| Phosphorus, mmoL/L | 1.8 (1.3–2.2) | 1.6 (1.5–2.3) | 0.802 |
| NT-proBNP, ng/ml | 9769.0 (3093.5–21941.0) | 3034.0 (1493.2–6503.0) | 0.002 |
| Cardiac troponin I, μg/L | 0.0 (0.0–0.4) | 0.0 (0.0–0.0) | 0.655 |
| Cardiac troponin T, pg/ml | 86.5 (50.2–173.9) | 72.6 (34.1–136.5) | 0.799 |
| Creative kinase MB, U/L | 12.0 (9.0–16.0) | 12.0 (8.5–15.5) | 0.929 |
| CARDIAC STRUCTURE AND FUNCTION | |||
| NYHA functional class | 0.656 | ||
| I | 0 | 2 | |
| II | 7 | 8 | |
| III | 13 | 10 | |
| IV | 1 | 1 | |
| LVEF, % | 63.0 (54.5–68.0) | 66 (49.0–71.0) | 0.875 |
| E/e' ratio | 17.3 (10.3–58.0) | 14.0 (10.3–36.7) | 0.291 |
| e', cm/s | 5.5 (3.0–10.0) | 4.0 (3.0–7.0) | 0.707 |
| TR, cm/s | 257.0 (218.8–331.0) | 237.0 (197.0–299.0) | 0.436 |
| LVDd, mm | 52.0 (49.0–60.0) | 50.0 (47.0–61.0) | 0.159 |
| AOR, mm | 21.0 (20.0–22.0) | 21.0 (19.8–22.3) | 1.000 |
| AAO, mm | 33.0 (30.5–35.0) | 33.5 (30.8–35.3) | 0.173 |
| LA, mm | 37.0 (35.5–40.5) | 38.0 (35.0–41.0) | 0.950 |
| RVDd, mm | 20.0 (19.5–22.0) | 21.0 (19.0–24.0) | 0.472 |
| IVSd, mm | 12.0 (10.0–13.0) | 12.0 (10.0–14.0) | 0.480 |
| CHEST RADIOGRAPHY | |||
| Cardiomegaly | 5/21 | 3/18 | 0.702 |
| Interstitial or alveolar edema | 0/21 | 0/18 | – |
| Pleural effusion | 7/21 | 3/18 | 0.290 |
| Vascular prominent hilum | 1/21 | 1/18 | 1.000 |
| Haziness of pulmonary vessels | 7/21 | 6/18 | 1.000 |
| ADVERSE EFFECTS | |||
| Hypotension | 0 (0.0) | 0 (0.0) | – |
| Hyperkalaemia | 0 (0.0) | 0 (0.0) | – |
| Angioedema | 0 (0.0) | 0 (0.0) | – |
Values are proportion or median and interquartile range (IQR). PD, peritoneal dialysis; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; eGRF, estimated glomerular filtration rate; UACR, urinary albumin creatinine excretion rate; EF, ejection fraction; TR, Tricuspid regurgitation peak velocity; AOR, aortic dimension; AAO, ascending aorta; LA, left atrium; RVDd, right ventricular diastolic diameter; IVSd, interventricular septum diastolic thickness; RVDd, right ventricular diastolic diameter.